WilliamHKreisleMD

Oncology • Boise, ID

Hematologic Oncology

Physician

Join to view full profile

Are you Dr. Kreisle?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
You already have 54 invites waiting!
Read the latest clinical news, personalized to your specialty.

Claim this profile

Not you? Find your profile

Office
100 E Idaho St
Boise, ID 83712
Phone+1 208-381-2709

Summary

Dr. William Kreisle, MD is an oncologist in Boise, Idaho. He is currently licensed to practice medicine in Idaho, Oregon, and Arizona. He is affiliated with St. Luke's Boise Medical Center.

Education & Training

University of Arizona College of Medicine-TucsonFellowship, Hematology and Medical Oncology, 1988 - 1991
University of Utah HealthResidency, Internal Medicine, 1985 - 1988
Baylor College of MedicineClass of 1985

Certifications & Licensure

AZ State Medical License 1989 - Present
ID State Medical License 1994 - 2026
OR State Medical License 1995 - 2025
UT State Medical License 1986 - 1992
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology

Clinical Trials

Rituxan/BEAM vs Bexxar/BEAM in Autologous Hematopoietic Stem Cell Transplant for Non-Hodgkin's Lymphoma (BMTCTN0401) Start of enrollment: 2005 Dec 01
Completed
Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65 Start of enrollment: 2010 Oct 01
Active, not recruiting
Phase 3
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

188 citations
Effect of Acupuncture vs Sham Acupuncture or Waitlist Control on Joint Pain Related to Aromatase Inhibitors Among Women With Early-Stage Breast Cancer: A Randomized Cl...
Dawn L. Hershman, Joseph M. Unger, Heather Greenlee, Jillian Capodice, Danika L. Lew
JAMA. 2018-07-10
3 citations
A phase I trial of 14-day continuous intravenous infusion mitoxantrone.
William H Kreisle, David S. Alberts, Alan F. List, Thomas M. McCloskey, Patricia M. Plezia
Anti-Cancer Drugs. 1991-06-01

Press Mentions

St. Luke's Now Collecting Donations for National Marrow Donor ProgramFebruary 8th, 2018

Professional Memberships

American College of Physicians - ACP
Member
American Society of Clinical Oncology - ASCO
Member